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Abstract  
 
Context: 45,X/46,XY mosaicism is a disorder of sex development leading to 
abnormal gonadal development and to unpredictable genital phenotype, growth 
and pubertal development.  
Case Description: A two year old male presented with a right impalpable testis. 
Blood karyotype was 46,XY. A laparoscopy performed for right orchidopexy 
revealed a right streak gonad with Mullerian structures, while on the left side a 
normal descended testis was present. The karyotype of the removed gonad was 
45,X/46,XY. The child grew along the 2nd centile, within the mid parental height 
(MPH) range, until the time of puberty, when linear growth worsened due to a 
lack of a pubertal growth spurt and growth hormone (GH) therapy was initiated. 
He developed spontaneous puberty (13 years of age) and he showed normal 
pubertal progression. However, from the age of 15 years, he had low normal 
testosterone, raised FSH and reduction of Anti-mullerian hormone and Inhibin B, 
possibly suggestive of declining testicular function. His final height was -2.24 
SDS (-2.4 SDS at GH start; MPH -1.6 SDS). 
Conclusions: Our case describes a mild male phenotype associated with 
45,X/46,XY mosaicism characterized by unilateral cryptorchidism, spontaneous 
onset of puberty and normal blood karyotype. The case illustrates the difficulties 
inherent in making a diagnosis of 45,X/46,XY mosaicism when there is no genital 
ambiguity, and makes the point that growth and testicular impairment may occur, 
mostly manifesting during adolescence. An early diagnosis is crucial to initiate 
careful monitoring for growth and pubertal disorders, increased tumor risk and 
fertility issues commonly seen in these children. 
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Précis 
Our case illustrates a very mild male 45,X/46,XY phenotype without ambiguous 
genitalia, with normal blood karyotype and with mosaicism detected only on the 
gonadal tissue. 
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 INTRODUCTION  
 
45,X/46,XY mosaicism is a rare (1.7/10000) sex chromosome disorder of sex 
development. Heterogeneous phenotypes have been associated with 45X/46XY 
mosaicism encompassing females with and without Turner syndrome stigmata 
and males with varying degrees of masculinisation of external genitalia [1]. The 
conventional karyotype studied in the peripheral lymphocytes has several 
limitations [2-3] and does not predict the chromosome constitution of other body 
tissues [4]. Indeed, in some cases, mosaicism can be detected in the gonadal tissue 
only.  
We describe the case of a boy presenting with a very mild genital phenotype, a 
normal peripheral karyotype, and diagnosed with 45X/46XY mosaicism on the 
gonadal karyotype only.    
 
CASE REPORT 
A two year old child, raised as a male, presented with an impalpable testis on the 
right side. He had normal phallic and scrotal development with a normally 
descended left gonad. The conventional blood karyotype was 46,XY in 30 cells 
examined. Right orchidopexy was attempted but, instead of a testis, a streak 
gonad with a fallopian tube was visualized on the right side. Subsequent 
examination under anaesthesia, with cystoscopy and laparoscopy, revealed a 
normal left palpable testis in the scrotum and a right streak gonad with 
surrounding tubular structures, possibly Mullerian remnants. The prostatic urethra 
and bladder were normal. The histology of the removed right gonad and 
surrounding structures demonstrated a fallopian tube, a small streak gonad with 
no identifiable seminiferous tubular or follicular structures, a uterus with normal 
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immature endometrium and myometrium, and some scattered male ductal 
structures. The gonadal karyotype revealed mosaicism with 45 X in 27 cells and 
46 XY in 13 cells analysed. 
Given the diagnosis of 45,X/46,XY mosaicism, the child started regular 
surveillance for growth and pubertal development, tumor risk, infertility and 
complications of Turner syndrome. No associated autoimmune, cardiac and 
urinary tract phenotypes were detected at diagnosis and during the follow-up. The 
patient’s growth pattern and pubertal progression are shown in Figure 1. Up to the 
age of 8 years, he demonstrated a normal growth velocity along the 2nd centile (-2 
SDS), appropriate for his mid-parental height (-1.6 SDS), and a joint decision was 
made with the family to wait before starting Growth Hormone (GH) treatment. At 
10.25 years, he showed a deceleration in his growth velocity (4.1 cm/year, -1.2 
SDS) with an advanced bone age of 11.5 years, giving a predicted adult height of 
156 cm (<-2 SDS). GH therapy was initiated (0.03 mg/kg/day and subsequently 
titrated by IGF-1 concentrations), with significant improvement of the growth rate 
after one year of treatment (8.2 cm/year, +3.3 SDS). At the age of 13.15 years, he 
spontaneously entered puberty. During the follow-up period, he progressed 
normally through puberty, but he showed a poor pubertal growth spurt. At the last 
follow-up (15.98 years), his near-final height was 155.4 cm (-2.24 SDS) and his 
pubertal staging was genitalia 4-5, pubic hair 4, axillary hair 1, with a left testis 
volume of 15-20 ml. At the last biochemical assessment, testosterone was at the 
lower end of the normal adult range, and FSH was slightly elevated (Table 1). 
Anti-mullerian hormone and Inhibin B performed on two occasions (13 and 15 
years of age) were normal, but showed a significant decrease over time (Table 1).  
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DISCUSSION 
45,X/46,XY mosaicism is a rare genetic finding, leading to complex management 
issues with respect to gender of rearing and to unpredictability of the genital and 
gonadal phenotype of the affected children [1,5]. The relative distribution of the 
45,X and 46,XY chromosomal cell lines among different tissues probably 
accounts for this wide phenotypic variation. The blood karyotype has several 
limitations: the number of cells examined can change the karyotype results and 
the percentage of the 45,X cell line can also decrease over time [3,5].  
Three cases have been reported so far of discordance between blood (46,XY) and 
gonadal (45,X/46,XY) karyotype [2,6,8]. Two patients presented with ambiguous 
genitalia at the age of 1 year [2] and with a left undescended testis and penoscrotal 
hypospadias at the age of 16 years [6], respectively. The third case was a neonate 
with ambiguous genitalia in whom chromosome Y-derived sequences were 
detected in the dysgenetic gonad and skin fibroblasts [8]. To our knowledge, our 
patient is the phenotypically mildest reported case of 45,X/46,XY mosaicism 
(isolated unilateral impalpable testis with normal male genitalia and spontaneous 
puberty) diagnosed only on the gonadal karyotype. Nonetheless, in keeping with 
previously reported cases [7], from the age of 15 years, our patient showed 
biochemical features of possible declining testicular function. It is well-known 
that the majority of 45,X/46,XY patients born with ambiguous genitalia are 
infertile. However, even in patients with mild phenotypes in childhood, 
spermatogenesis may be impaired in adulthood [7]. Therefore, at diagnosis, 
possibilities of fertility preservation should be discussed with the patient and his 
family [1]. 
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45,X/46,XY patients exhibit an increased tumor risk, not only when abdominal 
undifferentiated gonads are present, but also in dysgenetic or “apparently normal” 
intrascrotal testes [9,1,7]. In dysgenetic gonads, the formation of in situ 
gonadoblastoma or of an invasive germ cell tumor occurs in 15- 52% of cases [9]. 
However, the risk of germ cell malignancies is mainly defined by histological 
markers that do not distinguish “maturation-delayed” from “malignant” germ 
cells, probably leading to an over-diagnosis of cancer and also to over-treatment 
by gonadectomy [9, 10]. Although in the past gonadectomy was recommended, a 
more conservative approach is now preferred to allow endogenous hormone 
production and therefore spontaneous puberty, and to delay irreversible surgery 
until adulthood. Individualized management has recently been suggested in 
45,X/46,XY patients taking into consideration genetic factors, the localization of 
the gonad, the age and cooperation of the patient, and the histological and 
immunohistochemical findings [9-11]. However, it must be pointed out that the 
risk of progression from histologically malignant lesions to clinical disease with 
actual morbidity and risk of metastases in these patients is unknown. An 
international Disorders of Sex Development registry that currently exists will 
hopefully offer greater insights on the long-term morbidity and mortality 
associated with malignancies in these patients [11]. 
The evidence available on 45,X/46,XY patients suggests that no correlation exists 
between the clinical phenotype and the degree of mosaicism [4,5,7]. The pubertal 
course, the fertility outcome and the tumor risk seem to be predicted more by 
degree of genital ambiguity and gonadal differentiation than by the blood/gonadal 
karyotype [4,5,7]. However, most patients, including mild cases without genital 
ambiguity and those starting puberty spontaneously, will develop some testicular 
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impairment in adolescence or young adulthood [7]. In our case, the preserved 
gonad maintained sufficient Leydig cell function to induce puberty, but the 
current hormonal profile possibly suggests declining testicular function, raising 
concerns for future fertility. 
Growth seems to be consistently impaired in these patients [7]. Variable outcomes 
have been reported on GH treatment with a recent review concluding that, 
although there may be some short- to mid-term improvement in growth, long-term 
data on adult height are disappointing [12]. However, supraphysiological GH 
doses and earlier commencement might result in better outcomes, as could have 
possibly been the case in our patient. Since fibroblasts have the same 
mesenchymal origin as chondrocytes and osteoblasts, karyotype from skin 
fibroblasts could be more useful than the blood karyotype to predict the growth 
phenotype of these patients [12]. Furthermore, periodic screening for cardiac and 
autoimmune complications should be considered in 45,X/46,XY patients [13,14].  
Our case report highlights that 45,X/46,XY mosaicism may present with a very 
mild phenotype and a normal blood karyotype. Cases without genital ambiguity 
can be easily missed. However, short stature and decline in testicular function 
over time are common features, even in mild cases, and these patients also exhibit 
a significant risk of tumors and infertility. An early diagnosis of gonadal 
dysgenesis is therefore important in all cases to optimize growth, puberty and 
fertility outcomes, and to monitor for the increased tumor risk. 
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Figure 1. Patient’s growth pattern and pubertal progression. 
 
Table 1. Serial hormonal profiles. 
 2.00y 11.50y 13.16y 15.00y 15.98 y Reference ranges 
Testosterone  
nmol/L 
 
<0.69 
 
 
<0.69 
 
 
<0.69 
 
 
1.44 
 
 
11.00 
 
&Prepubertal: <0.5 
  Adult: 10-30 
LH 
IU/L 
< 0.7 <0.2 0.9 2.5 4.6 
&Prepubertal: <0.5 
  Tanner stage 2: 1-4 
  Tanner stage 4: 2-8 
FSH 
IU/L 
0.5 0.8 1.7 10.8 19.3 
&Prepubertal: 0.4-1.6 
  Tanner stage 2: 0.5-4.0 
  Tanner stage 3: 2.5-4.5 
  Tanner stage 4: 3.0-5.5 
Inhibin B 
pg/mL 
  229.4 47.7  # 12-17 years: 74-470 
AMH 
pmol/L 
  
 
353.5 
 
 
65.0 
 
 
*Tanner stage 3: 18 – 587 
  Tanner stage 4: 12 - 90 
Tanner stage G1,P1,A1 G2,P1,A1 G3,P2,A1 G4,P2,A1 G5,P3,A1 
 
 
Left 
testicular 
volume (ml) 
2 3 8 12-15    15-20   
 
y: years; m: months; G: genitalia stage, P: pubic hair stage, A: axillary hair stage, AMH: Anti-
mullerian hormone 
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